Bonadio RC, Tavares MC, Balint FC, de Sousa IM, et al. Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study. Breast Cancer Res Treat 2025 Feb 3. doi: 10.1007/s10549-025-07628.
PMID: 39899161